| KYV-101 / Kyverna |
NCT06193889: KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis |
|
|
| Recruiting | 2 | 20 | Europe, US | KYV-101, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Myasthenia Gravis, Generalized Myasthenia Gravis | 05/26 | 05/27 | | |
NCT06384976: KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis |
|
|
| Recruiting | 2 | 120 | US | KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB | Kyverna Therapeutics | Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS | 04/27 | 01/29 | | |
NCT06588491: KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD-19 CAR T) Therapy, in Subject With Treatment Refractory Stiff Person Syndrome |
|
|
| Recruiting | 2 | 25 | US | Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Stiff-Person Syndrome, SPS | 04/26 | 12/26 | | |
KYSA-3, NCT06342960: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
|
|
| Recruiting | 1/2 | 32 | Europe | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | 10/28 | 01/29 | | |
NCT06400303: KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis |
|
|
| Recruiting | 1/2 | 21 | US | KYV-101, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria | 03/26 | 03/27 | | |
COMPARE, NCT06475495: Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis |
|
|
| Not yet recruiting | 1/2 | 13 | NA | KYV101, Rituximab (active comparator) | Charite University, Berlin, Germany, Kyverna Therapeutics | Rheumatoid Arthritis | 03/27 | 03/27 | | |
| Not yet recruiting | 1/2 | 8 | NA | KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy | David Simon, Kyverna Therapeutics | ANCA-IgG-positive ANCA Associated Vasculitis | 01/27 | 07/27 | | |
NCT05938725: KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
|
|
| Recruiting | 1/2 | 32 | US | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV | 08/25 | 08/26 | | |
NCT06298019: Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis |
|
|
| Not yet recruiting | 1 | 21 | US | KYV-101 | Stanford University | Dermatomyositis | 04/27 | 04/39 | | |
NCT06138132: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis |
|
|
| Recruiting | 1 | 12 | US | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Bendamustine | Stanford University, Kyverna Therapeutics | Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | 06/27 | 06/27 | | |
NCT06451159: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis |
|
|
| Recruiting | 1 | 10 | US | KYV-101 (Biological) - 0.33 ×10^8 cells, CAR T-cell therapy, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU) | Bruce Cree, Kyverna Therapeutics | Progressive Multiple Sclerosis | 06/26 | 06/27 | | |
| Recruiting | 1 | 24 | US | KYV-101, Cyclophosphamide, Fludarabine | David Porter, Kyverna Therapeutics | Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis | 08/28 | 08/28 | | |
| KYV-201 / Kyverna, Intellia Therap |
| No trials found |
